Sign In
Buy KURA
$8.66
-0.315 (-3.51%)
At Close: Jun 03, 2026
Kura Oncology Appoints Carol Schafer to Board of Directors
07:30am, Friday, 04'th Jun 2021
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
20 Short Ideas With Super-Weak Momentum
10:39am, Monday, 31'st May 2021
Often, weak stocks going into a market correction or bear move will decline faster than the main indexes. I have listed 20 stocks/ETFs out of a 4000+ sort universe experiencing a rush of selling since
Kura Oncology to Participate in Cowen Virtual Oncology Innovation Summit
07:30am, Thursday, 13'th May 2021
SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment o
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q1 2021 Results - Earnings Call Transcript
09:47am, Sunday, 09'th May 2021
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q1 2021 Results - Earnings Call Transcript
Kura Oncology to Report First Quarter 2021 Financial Results
07:30am, Thursday, 29'th Apr 2021
SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology
04:08pm, Monday, 22'nd Mar 2021
– Phase 2 RUN-HN trial showed ORR of 55%, median PFS of 5.6 months and median OS of 15.4 months in recurrent/metastatic HRAS mutant HNSCC –
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q4 2020 Results - Earnings Call Transcript
01:43pm, Wednesday, 24'th Feb 2021
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q4 2020 Results - Earnings Call Transcript
Kura Oncology Receives FDA Breakthrough Therapy Tag For Tipifarnib In Head & Neck Cancer
09:12am, Wednesday, 24'th Feb 2021
The FDA has designated Breakthrough Therapy status to Kura Oncology Inc's (NASDAQ: KURA) tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for head and neck cancer. The status
Kura Oncology Reports Fourth Quarter and Full Year 2020 Financial Results
07:20am, Wednesday, 24'th Feb 2021
– Preliminary clinical data for menin inhibitor KO-539 highlighted by single-agent activity in relapsed/refractory AML, including patients with NPM1 mutations –
Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma
07:00am, Wednesday, 24'th Feb 2021
SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology to Participate in Four Upcoming Investor Conferences
07:30am, Thursday, 18'th Feb 2021
SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology to Report Fourth Quarter and Full Year 2020 Financial Results
07:30am, Wednesday, 17'th Feb 2021
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology to Participate in H.C. Wainwright BioConnect 2021 Conference
07:30am, Thursday, 07'th Jan 2021
– Panel discussion on precision medicine to be hosted by former FDA Commissioner Dr. Scott Gottlieb – – Panel discussion on precision medicine to be hosted by former FDA Commissioner Dr. Scott G
Kura Oncology to Present at J.P. Morgan Healthcare Conference
07:30am, Wednesday, 06'th Jan 2021
SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
04:05pm, Friday, 11'th Dec 2020
SAN DIEGO, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
